FDA.reportPublic FDA data

antihemophilic factor (recombinant) pegylated-exei 1 UNT Injection

RxCUI
2275724
RxNorm name
antihemophilic factor (recombinant) pegylated-exei 1 UNT Injection
Display name
antihemophilic factor (recombinant) pegylated-exei 1 UNT Injection
Full name
antihemophilic factor (recombinant) pegylated-exei 1 UNT Injection
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:38:59

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125671EsperoctAntihemophilic Factor (Recombinant), GlycoPEGylated-exei351(a)Rx2026-08-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
562f94e8-825f-4d7f-b93c-b783ac3a43bcantihemophilic factor (recombinant) pegylated-exei 1 UNT Injection [PSN] · antihemophilic factor (recombinant) pegylated-exei 1 UNT Injection [SCD]27These highlights do not include all the information needed to use ESPEROCT ® safely and effectively. See full prescribing information for ESPEROCT. ESPEROCT [antihemophilic factor (recombinant), glycopegylated-exei] lyophilized powder for solution, for intravenous use Initial U.S. Approval: 201920240701